We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

000661:SZSEChangchun High-Tech Industry (Group) Co., Ltd. Analysis

Data as of 2026-06-17 - not real-time

CN¥63.79

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

The stock is trading at 63.79 CNY, well below its 20‑day, 50‑day and 200‑day simple moving averages of 70.70, 79.81 and 97.29, signaling a persistent bearish bias. Technical momentum is weak, with a bearish MACD (line below signal) and a negative histogram, while the RSI of 22.5 indicates deep oversold conditions that could trigger a short‑term bounce. Current price hovers just above the identified support level of 63.51 and far below the resistance near 81.78, suggesting limited upside unless fundamentals improve. Volatility is elevated at over 30% (30‑day), yet beta remains low at 0.31, implying the stock moves more on company‑specific factors than market swings. Fundamentally, the company reports a negative profit margin (-0.36%) and a trailing EPS of -0.09, with a forward EPS of 11.04 that drives a modest forward P/E of 5.78. The balance sheet is strained: debt‑to‑equity sits at a high 7.94 and free cash flow is negative, while the dividend payout ratio exceeds 100%, raising questions about dividend sustainability. A discounted cash‑flow model values the firm at roughly 35.94 CNY, far below the market price, reinforcing the view that the stock is currently overvalued.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • Price below all major moving averages
  • Bearish MACD and negative histogram
  • High debt‑to‑equity ratio

Medium Term

1–3 years
Cautious
Model confidence: 8/10

Key Factors

  • Negative earnings and thin profit margin
  • Dividend payout exceeding earnings
  • DCF fair value far below market price

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Potential pipeline of biopharmaceutical products
  • Low beta indicating limited market‑wide volatility
  • Sector demand for specialty generics in China

Key Metrics & Analysis

Financial Health

Revenue Growth-13.70%
Profit Margin-0.36%
P/E Ratio5.8
ROE-0.86%
ROA0.87%
Debt/Equity7.94
P/B Ratio1.1
Op. Cash FlowCN¥1.3B
Free Cash FlowCN¥-910072320
Industry P/E24.3

Technical Analysis

TrendBearish
RSI22.5
SupportCN¥63.51
ResistanceCN¥81.78
MA 20CN¥70.70
MA 50CN¥79.81
MA 200CN¥97.29
MACDBearish
VolumeIncreasing
Fear & Greed Index88.64

Valuation

Fair ValueCN¥35.94
Target PriceCN¥111.34
Upside/Downside74.54%
GradeOvervalued
TypeValue
Dividend Yield0.25%

Risk Assessment

Beta0.31
Volatility30.18%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.